Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study

Henry, N. L., Pchejetski, D. ORCID: https://orcid.org/0000-0003-1074-9261, A'Hern, R., Nguyen, A. T., Charles, P., Waxman, J., Li, L., Storniolo, A. M., Hayes, D. F., Flockhart, D. A., Stearns, V. and Stebbing, J. (2010) Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study. British Journal of Cancer, 103 (3). pp. 291-296. ISSN 0007-0920

Full text not available from this repository. (Request a copy)

Abstract

The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.

Item Type:	Article
Uncontrolled Keywords:	aged,androstadienes,antineoplastic agents,aromatase inhibitors,breast neoplasms,bridged compounds,case-control studies,cytokines,estrogens,female,humans,inflammation,middle aged,musculoskeletal diseases,postmenopause,syndrome,tamoxifen,taxoids
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	Pure Connector
Date Deposited:	16 Dec 2014 10:06
Last Modified:	18 Jun 2026 16:39
URI:	https://ueaeprints.uea.ac.uk/id/eprint/51536
DOI:	10.1038/sj.bjc.6605768

Actions (login required)

View Item